Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: dabrafenib

First Posted Date: 2016-08-02

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT02852239

Locations: 🇺🇸
Omega Research Consultants LLC, DeBary, Florida, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸
Wake Research Associates Oncology, Raleigh, North Carolina, United States

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Phase 4

Completed

Conditions: Pancreatic Neuroendocrine Tumors

Interventions: Drug: everolimus

First Posted Date: 2016-07-25

Last Posted Date: 2024-03-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 61

Registration Number: NCT02842749

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: BLZ945
Drug: PDR001

First Posted Date: 2016-07-12

Last Posted Date: 2024-01-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 192

Registration Number: NCT02829723

Locations: 🇺🇸
Dana Farber Cancer Institute Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan
🇺🇸
Sarah Cannon Research Institute Sarah Cannon Research, Nashville, Tennessee, United States

and more 2 locations

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: IDH305

First Posted Date: 2016-07-11

Last Posted Date: 2019-04-10

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02826642

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Secukinumab
Drug: Ustekinumab

First Posted Date: 2016-07-11

Last Posted Date: 2019-07-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1114

Registration Number: NCT02826603

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Pancreatic Carcinoma
Triple Negative Breast Cancer
Melanoma
Endometrial Carcinoma

Interventions: Drug: MCS110
Drug: PDR001

First Posted Date: 2016-06-21

Last Posted Date: 2021-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 141

Registration Number: NCT02807844

Locations: 🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇨🇭
Novartis Investigative Site, Zuerich, Switzerland

and more 2 locations

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

Not Applicable

Completed

Conditions: Chronic Heart Failure (CHF)

Interventions: Procedure: Standard care

First Posted Date: 2016-06-21

Last Posted Date: 2021-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1415

Registration Number: NCT02807857

Locations: 🇪🇸
Novartis Investigative Site, Panxon, Spain

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Phase 4

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Secukinumab 300 mg
Drug: Secukinumab 150 mg
Other: Placebo

First Posted Date: 2016-06-14

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 258

Registration Number: NCT02798211

Locations: 🇵🇷
Novartis Investigative Site, Santurce, Puerto Rico

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1

Completed

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Spartalizumab
Drug: Capmatinib

First Posted Date: 2016-06-10

Last Posted Date: 2023-07-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT02795429

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

Phase 3

Withdrawn

Conditions: Psoriasis

Interventions: Drug: "Secukinumab" "Cosentyx TM"

First Posted Date: 2016-06-10

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02795416

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy